Key Highlights

  • Johnson & Johnson (NYSE:JNJ) reports before the open on October 13, 2026, and consensus is USD 2.53 to USD 2.54 in earnings per share on about USD 25.4 billion in revenue, per published estimates.
  • The date is verified and the EPS estimate differs by one cent between providers, but the results were not yet out at about 6:30 a.m. ET, so no outcome or market reaction can be reported.
  • Health care outperformed in the October 12, 2026 session, which has revived the question of whether Johnson & Johnson (NYSE:JNJ) is a defensive haven if rates rise and growth stocks weaken.
  • The Dow Jones Industrial Average closed at 51,850.55, up 0.38%, while the Nasdaq Composite fell 0.44% to 27,245.90 on October 12, 2026, a split that supports the defensive rotation argument.

The Setup Before the Open

Per published estimates, Johnson & Johnson (NYSE:JNJ) is expected to post earnings per share of USD 2.53 to USD 2.54 on revenue of about USD 25.4 billion. The one-cent gap reflects the use of different providers, so the article uses the range. The company has two main businesses, innovative medicine, which sells prescription drugs, and medical technology, which sells devices used in surgery and other procedures. That mix gives the company revenue from both patent-protected drugs and hospital procedures. Consensus is an average of analyst forecasts and not a company forecast, so investors will compare the actual result with it and with prior guidance. Results were not available when this was written, and the share reaction will depend on guidance as much as on the quarter itself.

Is It a Defensive Haven?

The label defensive refers to businesses whose demand changes little through the economic cycle. People still need medicines and medical procedures when growth slows, which is why health care often attracts money in rotations away from technology. On October 12, 2026 health care outperformed while the Nasdaq fell 0.44%, which fits that pattern. The mechanism has limits, however. Drug makers face patent expiries, pricing pressure from government programs and legal costs, and device makers depend on hospital volumes. A defensive reputation also does not protect a share price from a weak outlook. Johnson & Johnson (NYSE:JNJ) therefore has to deliver on guidance, not only on the quarter, if the safe-haven argument is to hold.

Risks and What to Watch

Investors can watch several items in the release and the call. Guidance for full-year earnings is the first, since a raise or cut often moves the shares more than the quarter. Segment growth in medicine and technology is second, and commentary on pricing and procedure volumes is third. Rates are a wider factor. With the 10-year Treasury yield at 5.24% on the October 12, 2026 reading, income-oriented stocks compete with bonds for capital, which can weigh on defensive names. The September consumer price index on October 14 could shift that balance. Nothing here is a forecast, and the result may differ from published estimates. Results will follow the company release.

Where Things Stand

Johnson & Johnson (NYSE:JNJ) is not a guaranteed haven. Its business is less tied to the economic cycle than many sectors, and health care outperformed on October 12, 2026, but the stock still depends on guidance, drug pricing and device volumes. Results were not out at 6:30 a.m. ET, and consensus of USD 2.53 to USD 2.54 per share is the bar the company release will be measured against before the open.